Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
ETFs with exposure to Axsome Therapeutics, Inc. (AXSM)
4.96% | +8.17% | +18.54% | €0 | €0 | €5M | 0.47% | ||
First Trust NYSE Arca Biotechnology UCITS ETF - Acc - USD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 3.95% | +13.01% | +20.93% | -€1.8M | -€2.8M | €11M | 0.6% | |
First Trust NYSE Arca Biotechnology Index Fund ETF - USD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 3.92% | +12.43% | +20.36% | -€65M | +€908M | €2.45B | 0.54% | |
First Trust NYSE Arca Biotechnology ETF - CAD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 3.92% | +15.21% | +23.93% | +€529K | +€1.9M | €3.6M | 0.71% | Not rated |
Invesco DWA Healthcare Momentum ETF - USD This ETF provides exposure to Other US Health Care Equities | 2.97% | +18.18% | +20.89% | +€344K | -€8.6M | €122M | 0.72% | |
2.89% | +4.50% | +12.16% | -€1.8M | +€70M | €80M | 0.8% | Not rated | |
F/m Emerald Life Sciences Innovation ETF - USD This ETF provides exposure to Other Mid and Small-Cap Equities | 2.89% | +17.63% | +24.06% | +€1M | +€5.3M | €108M | 0.79% | Not rated |
State Street SPDR S&P Pharmaceuticals ETF - USD This ETF provides exposure to Equally Weighted US Pharmaceuticals Equities | 2.66% | +13.95% | +16.85% | +€24M | +€119M | €371M | 0.35% | |
2.65% | +9.19% | +16.62% | +€134M | +€128M | €997M | 0.38% | ||
Virtus Silvant Small/Mid Growth ETF - USD This ETF provides exposure to Other Mid and Small-Cap US Equities | 1.64% | +2.48% | +11.38% | €0 | +€2.7M | €3.1M | 0.39% | Not rated |
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
